JUN 08, 2020 3:02 PM PDT

Using Soft Tissue Sarcoma's Immune Defense as a Biomarker

WRITTEN BY: Jasper Cantrell

Programmed cell death protein 1 (PD-1) has been a big player in the treatment of both autoimmune disease and cancer. PD-1 is a receptor on the cell membrane that promotes cellular apoptosis, or cell death, in T-cells. It also prevents apoptosis in regulatory T-cells, which usually suppresses the immune response. Programmed death-ligand 1 (PD-L1) Is the trigger factor that initiates PD-1 signaling. Many cancers overexpress PD-L1, which creates an immunosuppressive environment and protects the tumor from the innate anti-cancer immune response. PD-1 inhibitors have had success in preventing this, promoting anti-cancer activity through the innate immune response.

Although these interactions are well studied in many cancer types, this not the case for soft tissue sarcomas (STSs). STSs are rare malignant neoplasms, with as many as 40% of patients seeing metastatic recurrence post-operation. A team from the Mie University School of Medicine in Japan hypothesized that the blood soluble PD-L1 (sPD-L1) would create an immunosuppressive environment around STS tumors and could be used as a prognostic biomarker in STS treatment.

Using data from 135 STS patients enrolled in the program at the university, the team began their analysis. The first observation they made was that compared to healthy volunteers, STS, and benign tumor patients had increased PD-L1 levels overall. Benign and STS tumors did not have a significant difference in sPD-L1 levels, however. Late-stage STS patients who developed metastasis, as well as those who unfortunately passed, were observed to have higher sPD-L1 concentrations than the rest of the patient group. Statistical analysis confirmed the correlation of high sPD-L1 levels and a low metastatic-free survival and overall-survival rate in patients with late-stage STSs.

The results of this study were not the clearest support of sPD-L1 and STS prognosis. Late-stage STS patients were the only patients with a clear correlation between sPD-L1 levels and overall survival rates or metastasis-free survival rates. The team admits to the limitations of the relatively small patient group, with possible bias from the large number of late-stage STSs. The type of STSs ranged across twenty sub-types as well, possibly clouding the data. Even with these limitations, the results show that sPD-L1 may be a useful biomarker for late-stage STS prognosis, and further study might reveal even more uses.

Sources: Nature, ImmunoOncology

About the Author
Bachelors of the Sciences
Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
NOV 28, 2022
Cell & Molecular Biology
From sample collection straight to RT-qPCR
NOV 28, 2022
From sample collection straight to RT-qPCR
Skip the nucleic acid purification step in your cancer detection workflow. Learn more about how Thermo Fisher Scientific ...
AUG 03, 2022
Cancer
Guide to Adherent Cell Culture Basics: Seeding, Expanding, and Harvesting
AUG 03, 2022
Guide to Adherent Cell Culture Basics: Seeding, Expanding, and Harvesting
Cell culturing is hard work. Because it's a highly technical process, there's a lot that can go wrong  ...
SEP 21, 2022
Cancer
Technology for Monitoring Tumors in Pre-Clinical Studies
SEP 21, 2022
Technology for Monitoring Tumors in Pre-Clinical Studies
Pre-clinical modeling, often using laboratory mice, is essential in developing life-saving therapies to treat cancer and ...
OCT 13, 2022
Cell & Molecular Biology
How the Tumor Microenvironment Can Disarm Immunity
OCT 13, 2022
How the Tumor Microenvironment Can Disarm Immunity
Cancer is basically what happens when cells start growing and dividing uncontrollably, and it gets worse when those canc ...
NOV 09, 2022
Cardiology
Less Than 5 Hours of Sleep Per Night Linked to Multiple Diseases
NOV 09, 2022
Less Than 5 Hours of Sleep Per Night Linked to Multiple Diseases
Getting enough sleep is an important part of lowering chronic disease risk.
NOV 29, 2022
Cancer
Some Pediatric Cancer Survivors Experience Premature Aging
NOV 29, 2022
Some Pediatric Cancer Survivors Experience Premature Aging
Aging occurs when molecular damage accumulates in cells and tissues throughout the body resulting in dysfunction and dys ...
Loading Comments...